沙库巴曲缬沙坦对冠心病不稳定型心绞痛合并慢性心力衰竭患者的影响分析  

Analysis of the Effects of Sacubitril/Valsartan on Patients with Unstable Angina Pectoris Complicated by Chronic Heart Failure

作　　者：韩红强 马旭阁 李世勋[1] HAN Hongqiang;MA Xuge;LI Shixun(Department of CardiologyⅡ,Xinxiang Central Hospital,Xinxiang Henan 453000,China)

机构地区：[1]新乡市中心医院心血管内科二,河南新乡453000

出　　处：《临床研究》2025年第5期54-56,共3页Clinical Research

摘　　要：目的探究沙库巴曲缬沙坦在冠心病(CHD)不稳定型心绞痛(UA)合并慢性心力衰竭(CHF)患者中的应用效果。方法将新乡市中心医院2023年2月至2024年9月收治的68例UA合并CHF患者作为研究对象,采用随机数表法为对照组(尼可地尔、呋塞米等常规治疗)与研究组(常规治疗基础上联用沙库巴曲缬沙坦治疗),各34例。比较两组心绞痛评分、心室重构指标、心血管事件发生率及不良反应。结果研究组治疗后的西雅图心绞痛量表评分高于对照组,差异有统计学意义(P<0.05)。研究组治疗后的左室射血分数高于对照组,且左心室收缩末期容积、舒张末期容积、左心室质量指数均低于对照组,差异均有统计学意义(P<0.05)。研究组心血管事件发生率低于对照组,差异具有统计学意义(P<0.05)。两组不良反应发生率差异无统计学意义(P>0.05)。结论对UA合并CHF患者予以沙库巴曲缬沙坦联合治疗,可进一步缓解其心绞痛症状,抑制心室重构,预防多种心血管事件,避免过度增加药物不良反应。Objective To explore the application effects of Sacubitril/Valsartan in patients with coronary heart disease(CHD)presenting with unstable angina(UA)complicated by chronic heart failure(CHF).Methods A total of 68 patients with UA and CHF treated at Xinxiang Central Hospital from February 2023 to September 2024 were selected for the study.They were randomly divided into two groups:the control group(treated with Nicorandil,Furosemide,and other conventional therapies)and the study group(treated with standard therapies plus Sacubitril/Valsartan),with 34 patients in each group.Pain scores,ventricular remodeling indicators,incidence of cardiovascular events,and adverse reactions were compared between the two groups.Results After treatment,the Seattle Angina Questionnaire scores in the study group were higher than those in the control group,with significant statistical differences(P<0.05).The left ventricular ejection fraction in the study group was higher than in the control group,while the left ventricular end-systolic volume,end-diastolic volume,and left ventricular mass index were lower in the study group,all with statistically significant differences(P<0.05).The incidence of cardiovascular events was lower in the study group compared to the control group,also with statistically significant differences(P<0.05).The incidence of adverse reactions between the two groups showed no statistically significant differences(P>0.05).Conclusion Treatment with Sacubitril/Valsartan combined with conventional therapy for patients with UA and CHF can further alleviate angina symptoms,inhibit ventricular remodeling,prevent various cardiovascular events,and avoid excessive increases in adverse drug reactions.

关 键 词：尼可地尔 沙库巴曲缬沙坦 不稳定型心绞痛 心室重构 慢性心力衰竭 

分 类 号：R972[医药卫生—药品]